Materialise NV — FY2021 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing; the supplied filing text does not provide a clear set of Q4-only financial results. Financial statements are prepared under IFRS as issued by the IASB and reported in euros.
Business context and financial performance
Materialise provides additive-manufacturing software, medical software and devices, and 3D-printing and manufacturing services. Its reportable segments are Materialise Software, Materialise Medical and Materialise Manufacturing.
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | €205.5 million | €170.4 million |
| Gross profit / margin | €118.2 million / 57.5% | €94.0 million / 55.2% |
| Operating profit (loss) | €12.2 million | (€4.6 million) |
| Net profit (loss) | €13.1 million | (€7.2 million) |
| Basic and diluted EPS | €0.23 | (€0.13) |
| Adjusted EBITDA (non-IFRS) | €32.5 million; 15.8% of revenue | €20.4 million; 12.0% of revenue |
| Cash flow from operations | €25.8 million | €30.0 million |
| Capital expenditure | €11.7 million | €17.7 million |
| Cash and cash equivalents at year-end | €196.0 million | €111.5 million |
| Loans, borrowings and lease liabilities | €99.1 million | €115.1 million |
Revenue increased 20.5% year over year, but remained about 4% above 2019. Operating cash flow declined despite the earnings recovery, with the company attributing the decrease primarily to working-capital effects from revenue growth. Financing cash flow was €71.2 million, including €88.1 million from the recorded capital increase; cash rose by €83.9 million overall. The company said it had sufficient liquidity for the next 12 months, but had no undrawn credit lines at year-end. It reported compliance with its debt covenants.
Segments and changes versus prior periods
| Segment | FY2021 revenue | Change vs. FY2020 | FY2021 Adjusted EBITDA margin |
|---|---|---|---|
| Software | €42.9 million | +9.9% | 36.6% |
| Medical | €73.4 million | +18.9% | 28.2% |
| Manufacturing | €89.2 million | +28.2% | 7.0% |
All three segments grew. Medical revenue benefited from medical devices and services, particularly CMF, and greater recurring medical-software revenue. Manufacturing recovered strongly in the second half, though automotive, aerospace and some industrial activity remained below 2019 levels. Software growth included a 27.6% rise in non-recurring revenue, while recurring software revenue declined 1.9%. The consolidated margin improvement reflected revenue growth, better production utilization and efficiencies.
In comparison, FY2020 revenue had fallen 13.3% from 2019 and the company recorded a net loss; the Manufacturing segment was particularly affected. FY2021 returned the company to profit, while revenue remained below the 2019 level.
Outlook, risks, contingencies and unusual items
- Outlook: Management provided no quantified revenue or earnings guidance in the supplied text. Its strategy emphasizes cloud-based software, Link3D integration, medical planning and personalized devices, and certified additive manufacturing for end-use parts. Management cautioned that cloud migration may affect near-term revenue and that continued investment is planned.
- COVID-19 and Ukraine: COVID-19 continued to affect certain business lines, especially in the first half of 2021. After Russia’s February 2022 invasion, the Kyiv office’s operations stopped; most staff continued remotely or relocated, but staffing, operating costs, service capacity and product-release timing remained uncertain. The company expected Russia-related sanctions to negatively affect 2022 revenue.
- Inflation and supply: Management cited rising wages, materials, energy and service costs, and uncertainty about passing these increases through to customers. Reliance on a limited number of suppliers for some consumables may also disrupt production or pressure margins.
- Internal controls: Management and the independent auditor concluded that internal control over financial reporting was ineffective at December 31, 2021 because monitoring controls were insufficient, including due to limited resources. No material financial-statement misstatements were identified, and the financial-statement audit opinion was unqualified. Further remediation was planned for 2022.
- Legal matters: A final judgment required payment of approximately €0.87 million to Dentsply Implants; payment was made in November 2021. Zimmer Biomet initiated arbitration over alleged indemnification obligations arising from a patent settlement; Materialise intends to contest the claim, and no amount was accrued.
- Other unusual items: 2021 financial income included substantial foreign-exchange gains, including gains related to U.S.-dollar offering proceeds. Materialise wrote its Essentium equity investment down to zero, recording a €3.4 million loss in other comprehensive income. A €0.2 million goodwill impairment was recorded for Aldema. The 2020 comparison included €4.6 million of impairments and a gain on remeasurement of Materialise Motion.
- Acquisition after year-end: Materialise completed its acquisition of Link3D on January 4, 2022 for stated consideration of $30.2 million. Link3D was not yet consolidated in FY2021 results.
- Shareholder matters: Materialise raised approximately $105 million net in a July 2021 follow-on offering; year-end shares outstanding were 59.1 million versus 54.2 million a year earlier. The company had no present intention to pay dividends.
Most important facts for investors to verify
- Confirm the full-year figures against the audited financial statements; do not treat them as Q4-only results.
- Track operating cash flow and working-capital needs alongside earnings, and reconcile cash raised in the offering with the reported cash-flow and equity statements.
- Assess whether the Manufacturing segment can sustain margin improvement and recover to pre-pandemic activity levels.
- Monitor the Ukraine workforce and product-development effects, inflation and supply-chain pressures, and the company’s 2022 trading updates.
- Review progress remediating the material weakness in financial-reporting controls and any subsequent auditor assessment.
- Follow the Zimmer Biomet arbitration, Link3D integration and acquisition accounting, and any related costs or dilution.
- Consider concentration: one medical customer generated €26.8 million, more than 10% of FY2021 revenue.